Generic placeholder image

Current Pharmacogenomics and Personalized Medicine


ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Review Article

Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review

Author(s): Jesus Rodriguez-Pascual* and Antonio Cubillo

Volume 15, Issue 2, 2017

Page: [81 - 85] Pages: 5

DOI: 10.2174/1875692115666170815161754

open access plus


Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.

Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.

Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.

Graphical Abstract

© 2022 Bentham Science Publishers | Privacy Policy